According to patent filed 4/30, not only is once nightly beneficial in eliminating need to wake for 2nd dose (convenience and eliminating break in REM cycle) but blood concentration at wake is < than Xyrem. Hangover effect & risk of falling upon waking signif reduced. 
Xyrem sales approx $1.4 billion or 3/4 total company sales. FT-218 would expand market and extend patent life. How can they not buy or license FT-218? How much is it worth to even before a phase 3 readout? $500 mln? $1 Bln? $1.5 Bln?
@AvadelPharma should host a conference call following #Sleep2019 to discuss the recent patent grant. It would help investors and the patient community understand the importance of this pharmacokinetic data and the increase in the QOL of #narcolepsy and #cataplexy patients.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
